Dr. Reddy's Laboratories announces the launch of Atomoxetine Capsules, USP in the U.S. Market
Deepthi | Myequity news | Date : 31-10-2018 12:50:00 IST
Dr. Reddy's Laboratories Ltd, today launched the Atomoxetine Capsules, USP, a therapeutic equivalent generic version of Strattera® (atomoxetine) Capsules (a registered trademark of Eli Lilly and Company) in the United States market approved by the U.S. Food and Drug Administration (USFDA).
Dr. Reddy's Atomoxetine Capsules, USP is available in 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg with 30 counts bottle size.
The Strattera® brand and generic had U.S. sales of approximately $304 million MAT for the most recent twelve months ending in August 2018 according to IMS Health*.
About Dr. Reddy's:
Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APls, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.